RESUMEN
Ro 63-1908, 1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol, is a novel subtype-selective N-methyl-D-aspartate (NMDA) antagonist that has been characterized in vitro and in vivo. Ro 63-1908 inhibited [(3)H]dizocilpine ((3)H-MK-801) binding in a biphasic manner with IC(50) values of 0.002 and 97 microM for the high- and low-affinity sites, respectively. Ro 63-1908 selectively blocked recombinant receptors expressed in Xenopus oocytes containing NR1C + NR2B subunits with an IC(50) of 0.003 microM and those containing NR1C + NR2A subunits with an IC(50) of >100 microM, thus demonstrating greater than 20,000-fold selectivity for the recombinant receptors expressing NR1C + NR2B. Ro 63-1908 blocked these NMDA NR2B-subtype receptors in an activity-dependent manner. Ro 63-1908 was neuroprotective against glutamate-induced toxicity and against oxygen/glucose deprivation-induced toxicity in vitro with IC(50) values of 0.68 and 0.06 microM, respectively. Thus, the in vitro pharmacological characterization demonstrated that Ro 63-1908 was a potent and highly selective antagonist of the NR2B subtype of NMDA receptors. Ro 63-1908 was active against sound-induced seizures (ED(50) = 4.5 mg/kg i.p. when administered 30 min beforehand) in DBA/2 mice. The dose required to give a full anticonvulsant effect did not produce a deficit in the Rotarod test. NMDA-induced seizures were also inhibited by Ro 63-1908 with an ED(50) of 2.31 mg/kg i.v. when administered 15 min before testing. Ro 63-1908 gave a dose-related neuroprotective effect against cortical damage in a model of permanent focal ischemia. Maximum protection of 39% was seen at a plasma concentration of 450 ng/ml. There were, however, no adverse cardiovascular or CNS side-effects seen at this dosing level.
Asunto(s)
Antagonistas de Aminoácidos Excitadores/farmacología , Fenoles/farmacología , Piperidinas/farmacología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Estimulación Acústica , Algoritmos , Animales , Anticonvulsivantes/farmacología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/ultraestructura , Corteza Cerebral/citología , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Electrofisiología , Antagonistas de Aminoácidos Excitadores/metabolismo , Técnicas In Vitro , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Infarto de la Arteria Cerebral Media/patología , Macaca fascicularis , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Fármacos Neuroprotectores/farmacología , Oocitos/efectos de los fármacos , Oocitos/metabolismo , Fenoles/metabolismo , Fenoles/farmacocinética , Piperidinas/metabolismo , Piperidinas/farmacocinética , Desempeño Psicomotor/efectos de los fármacos , Ratas , Receptores de N-Metil-D-Aspartato/metabolismo , Convulsiones/prevención & control , Vacuolas/efectos de los fármacos , XenopusRESUMEN
Starting from Ro-25-6981 as a lead compound, highly potent and selective NR1/2B subtype selective NMDA receptor antagonists, with low activity at alpha(1) adrenergic receptors were developed.
Asunto(s)
Antagonistas de Aminoácidos Excitadores/farmacología , Piperidinas/farmacología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Antagonistas de Aminoácidos Excitadores/síntesis química , Antagonistas de Aminoácidos Excitadores/química , Fenoles/síntesis química , Fenoles/química , Fenoles/farmacología , Piperidinas/síntesis química , Piperidinas/química , Receptores Adrenérgicos alfa 1/efectos de los fármacos , Receptores Adrenérgicos alfa 1/metabolismoRESUMEN
A method is reported by which agarose beads of diameter 1000 to 10000 microns can be prepared from Sepharose (R) 4B (native bead diameter 40 to 190 microns). Haemoperfusion experiments indicate that the enlarged beads are relatively haemocompatible; platelet loss is considerably less than that reported for many other bio-materials employed in haemoperfusion, and haemolysis is slight even after perfusion for several hours at flow-rates in excess of 25 ml/min. The beads can be activated by cyanogen bromide for the immobilisation of proteins. The sites for protein fixation are not restricted to the outside surface of the beads; small water soluble molecules, and serum proteins diffuse quite rapidly through the enlarged beads. A possible medical application of the large beads is in extracorporeal detoxification by chromatographic extraction or enzymatic modification, particularly of lipophilic toxins, using the enlarged beads as a carrier-matrix. The results described in this publication prove the viability of this concept. Such methods should be especially useful as artificial supports in fulminant hepatic failure.